Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate GSK1325760A - a Long-Term Extension Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who complete the 24-week administration of the Phase II/III study (Study No.AMB107816)~* Subjects who are assessed that the long-term extension administration of GSK1325760A is appropriate in the judgement of the investigator or subinvestigator~* Subjects who request the long-term extension administration of GSK1325760A, and agree to newly sign the informed consent form~Exclusion Criteria:~* Subjects who have been withdrawn from the Phase II/III study.~* Female subjects who wish to become pregnant.~* Treatment with other PAH medication is needed.~* A worsening of 2 or more levels of the WHO Functional Classification (see Appendix 2.1) comparing with the baseline of Phase II/III study (Study No.AMB107816).~* Worsening of right ventricular failure (e.g. as indicated by increased jugular venous pressure, new/worsened hepatomegaly, ascites, or peripheral edema) during Phase II/III study (Study No.AMB107816).~* Rapidly progressing cardiac, hepatic or renal failure during Phase II/III study (Study No.AMB107816).~* Participation to the long-term extension study is considered as inappropriate in the judgment of the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1325760A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).